Therapeutic Cloning Treats Parkinson's Disease in Mice
News Mar 25, 2008
Research led by investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) has shown that therapeutic cloning, also known as somatic-cell nuclear transfer (SCNT), can be used to treat Parkinson's disease in mice. The study's results are published in the March 23 online edition of the journal Nature Medicine.
For the first time, researchers showed that therapeutic cloning or SCNT has been successfully used to treat disease in the same subjects from whom the initial cells were derived. While this current work is in animals, it could have future implications as this method may be an effective way to reduce transplant rejection and enhance recovery in other diseases and in other organ systems.
In therapeutic cloning or SCNT, the nucleus of a somatic cell from a donor subject is inserted into an egg from which the nucleus has been removed. This cell then develops into a blastocyst from which embryonic stem cells can be harvested and differentiated for therapeutic purposes. As the genetic information in the resulting stem cells comes from the donor subject, therapeutic cloning or SCNT would yield subject-specific cells that are spared by the immune system after transplantation.
The new study shows that therapeutic cloning can treat Parkinson's disease in a mouse model. The scientists used skin cells from the tail of the animal to generate customized or autologous dopamine neurons—the missing neurons in Parkinson's disease.
The mice that received neurons derived from individually matched stem cell lines exhibited neurological improvement. But when these neurons were grafted into mice that did not genetically match the transplanted cells, the cells did not survive well and the mice did not recover.
The work was led by senior author Lorenz Studer, MD, Head of the Stem Cell and Tumor Biology Laboratory within the Sloan-Kettering Institute at MSKCC, and lead author Viviane Tabar, MD, Neurosurgeon and stem cell scientist at MSKCC. The work was performed in collaboration with scientists at the Riken Institute in Kobe, Japan.
More and more consumers are using services like 23andMe to learn about their genetic blueprint. Included with most of these services is the ability for users to download their "raw" genetic data, which can be further analyzed using third-party apps. But little is known about how and why consumers are using these apps, or about a variety of potential risks associated with these apps, until now.READ MORE